From GlobeNewswire: 2025-05-28 09:50:00

The Cardiac Marker Market is experiencing significant growth due to the rising prevalence of Cardiovascular diseases (CVDs) and advancements in diagnostic tools. The market is projected to reach US$28.27 billion by 2031, with a CAGR of 13.2% from 2025-2031. Key players driving this growth include Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers, offering high-sensitivity troponin assays and AI-integrated diagnostics for enhanced patient outcomes.

The increasing incidence of CVDs, such as heart attacks and stroke, has led to over 17 million deaths annually worldwide. Factors contributing to this rise include sedentary lifestyles, poor diet, and hypertension. As the prevalence of CVDs grows, early and accurate diagnostic tools like troponin and BNP biomarkers become crucial for patient care and treatment decisions.

Technological advancements in diagnostic tools, such as high-sensitivity assays and point-of-care testing devices, are transforming cardiac diagnostics. Automation, AI integration, and multiplex biomarker platforms allow for faster, more precise detection of CVDs, improving patient outcomes. These advancements in cardiac marker testing are essential for early intervention and personalized care.

In 2024, North America led the cardiac marker market, followed by Europe and Asia Pacific. Asia Pacific is projected to have the highest CAGR during the forecast period. The market is segmented by types of markers, indications, and end users, with troponin, acute coronary syndrome, and hospitals dominating their respective segments. This market segmentation reflects the diverse applications of cardiac markers in diagnosing and managing CVDs.

Key players like Abbott Diagnostics and Roche Diagnostics are at the forefront of developing new cardiac biomarkers like hs-cTnI and NT-proBNP. These advancements aim to improve the diagnosis and management of CVDs, offering healthcare providers more tools for patient care. Regulatory approvals, collaborations, and product launches in the cardiac marker market continue to drive innovation and growth.

The cardiac marker market is poised for sustained growth, driven by the increasing prevalence of CVDs and the demand for early diagnostics. Advancements in high-sensitivity assays, point-of-care testing, and AI integration are enhancing patient outcomes and clinical decision-making. With a focus on prevention and precision medicine, cardiac biomarkers play a crucial role in improving cardiovascular care globally.



Read more at GlobeNewswire: Cardiac Marker Market Size Projected to Reach USD 28.27